Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Thomas Eskew

Vascular Surgery Wilmington, NC Medical Doctor

NPI 1700866019 CMS profile 213526

1411 Physicians Dr, Wilmington, NC 28401

Open in the dashboard

General payments

$6,634

196 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Thomas Eskew of Wilmington, NC is reported in the CMS Open Payments database as having received $6,634 across 196 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 57th percentile of Vascular Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $635 16
2024 General $757 24
2023 General $1,289 45
2022 General $1,676 39
2021 General $1,059 31
2020 General $590 17
2019 General $627 24

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Thomas Eskew
  • Vascular Surgery median
  • Middle half of Vascular Surgery
  • National median

In program year 2025, general payments to Thomas Eskew were reported at $635. Among 3,991 Vascular Surgery profiles paid that year, the median was $924 and the middle half received between $273 and $2,636.

Show as a table
Year Thomas Eskew Vascular Surgery median Middle half National median
2019 $627 $796 $226–$2,363 $163
2020 $590 $348 $118–$1,110 $114
2021 $1,059 $471 $158–$1,421 $132
2022 $1,676 $725 $222–$2,183 $149
2023 $1,289 $836 $257–$2,440 $160
2024 $757 $909 $252–$2,619 $164
2025 $635 $924 $273–$2,636 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic, Inc. $1,232 23 payments
  2. Boston Scientific Corporation $1,163 44 payments
  3. Inari Medical, Inc. $532 5 payments
  4. W. L. Gore & Associates, Inc. $421 7 payments
  5. Imbed Biosciences Inc. $345 11 payments
  6. Medtronic Vascular, Inc. $305 6 payments
  7. Ethicon US, LLC $261 7 payments
  8. Janssen Pharmaceuticals, Inc $237 15 payments
  9. Bard Peripheral Vascular, Inc. $225 9 payments
  10. Silk Road Medical, Inc. $199 3 payments
  11. Other $1,713 66 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,616 195 payments
  2. Entertainment $18 1 payment
Products named General payments · program years 2019–2025
  1. FLOWTRIEVER CATHETER, S $772 7 payments
  2. ENDURANT IIS $668 12 payments
  3. CT THROMBECTOMY SYSTEM KIT $487 5 payments
  4. Heli-FX EndoAnchor System $325 6 payments
  5. General - Vascular Intervention $299 5 payments
  6. XARELTO $237 15 payments
  7. Endurant $215 2 payments
  8. CELT ACD $194 1 payment
  9. PROLENE $162 4 payments
  10. ENROUTE 0.014 Guidewire $161 1 payment
  11. Other $4,228 153 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 9 drugs

Part D claims

393

Median for General Surgery: 59

Drug cost

$57,237

Median for General Surgery: $393

Branded share of claims

71.8%

Median for General Surgery: 28.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 27 $24,160
Xarelto Rivaroxaban Brand 27 $23,858
Brilinta Ticagrelor Brand 11 $5,621
Clopidogrel Clopidogrel Bisulfate Brand 204 $1,813
Cilostazol Generic 61 $1,419
Gabapentin Generic 16 $128
Tramadol Hcl Generic 15 $99
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 13 $77
Furosemide Generic 19 $61

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 15,891 Part D prescribers listed as General Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 162 billing codes

Paid by Medicare

$916,597

Medicare's payments for the services billed

Medicare patients

1,180

Average age 76

Services billed

4,177

516 women, 664 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 54%
Ischemic heart disease 52%
Diabetes 38%
Chronic kidney disease 37%
Atrial fibrillation 28%
COPD 27%
Depression 26%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

196 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Vascular Surgery in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record